CG Oncology, based in Irvine, Calif., was founded in 2010 by CEO Arthur Kuan. The company, which was last valued at $405 million in September 2022, is a developer of genetically engineered oncolytic immunotherapy treatments for individuals with advanced cancer.
Last September, the company announced an oversubscribed $120 million Series E funding round led by ORI Capital, Longitude Capital and Decheng Capital. The company said it will use the new capital to advance its lead programs toward FDA review and broaden its drug pipeline to address other unmet needs in urologic cancer. Its lead drug candidate, CG0070, has reached Phase 3 testing as a monotherapy for non-muscle invasive bladder cancer.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
CG Oncology does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for CG Oncology will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 9/30/2022 | Series E | $120MM raised | $XXX.XX | $XXX.XX |
| 12/10/2020 | Series D | $47.3MM raised | $XXX.XX | $XXX.XX |
| 3/18/2019 | Series C | $22MM raised | $XXX.XX | $XXX.XX |
| 8/5/2015 | Series B | $10MM raised | $XXX.XX | $XXX.XX |
| 7/28/2014 | Series A-1 | $3.57MM raised | $XXX.XX | $XXX.XX |
CG Oncology is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own CG Oncology pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
CG Oncology is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
